# China NMPA Product Recall - SynchroMed II Drug Infusion System

Source: https://www.globalkeysolutions.net/records/china_product_recall/medtronic-inc/395b8cff-ec31-41d7-8119-51a27ca3a047/
Source feed: China

> China NMPA product recall for SynchroMed II Drug Infusion System by Medtronic Inc. published April 10, 2012. Recall level: . The National Medical Products Administration (NMPA) published an alert on April 10, 2012, regarding 

---

## Details

- Record Type: CHINA_PRODUCT_RECALL
- Title: Medtronic Inc. is recalling the SynchroMed II drug infusion system.
- Company Name: Medtronic Inc.
- Publication Date: 2012-04-10
- Product Name: SynchroMed II Drug Infusion System
- Recall Reason: Some batteries may experience an increase in impedance under normal flow conditions, leading to premature elective replacement indication (ERI) or unacceptable low voltage supply. This can also occur during high current demand processes, such as when a bolus injection causes a low battery voltage reset.
- Discovering Company: Medtronic China Co., Ltd. Beijing Office
- Manufacturing Company: Medtronic Inc.
- Summary: The National Medical Products Administration (NMPA) published an alert on April 10, 2012, regarding a voluntary global recall initiated by Medtronic Inc. concerning certain SynchroMed II Drug Infusion Systems. The affected models include 8637-20 and 8637-40. The primary issue identified was that some device batteries experienced increased impedance during normal operation. This degradation led to premature elective replacement indications (ERI), unacceptably low flow rates, and low battery voltage resets, with battery performance degrading significantly shorter than the expected seven-year lifespan. As of May 31, 2011, Medtronic confirmed 55 returned pumps globally exhibiting high battery impedance. Under the NMPA's regulatory oversight, Medtronic was required to implement specific corrective actions. This included submitting a physician notification letter and relevant attachments, delivered in person to healthcare providers. The notification process was scheduled to commence on December 3, 2011, with completion anticipated by December 20, 2011. Upon finalizing these notifications, Medtronic was obligated to submit a summary report to the NMPA. Additionally, the NMPA requested that regional food and drug administrations strengthen their supervision of such medical devices to ensure patient safety.

Company: https://www.globalkeysolutions.net/companies/medtronic-inc/398d5f72-c7d2-4c97-94fc-fbef4cf2336d/